Table 3.
Correlation of response with expression of molecular biomarkers
| Biomarker | Response |
All samples | ||
|---|---|---|---|---|
| No | Yes | |||
| Overall | 10 | 12 | 22 | |
| Phospho-CREB | # of tissue samplesa | 10 | 10 | 20 |
| Mean score (SD)b | 177 (115) | 141 (108) | 159 (110) | |
| CREB | # of tissue samples | 10 | 10 | 20 |
| Mean score (SD) | 267 (41) | 261 (43) | 264 (41) | |
| Dp-32/tDpc | # of tissue samples | 10 | 12 | 22 |
| Mean score (SD) | 282 (37) | 270 (75) | 275 (60) | |
| PTENd | # of tissue samples | 7 | 6 | 13 |
| Mean score (SD) | 53 (87) | 127 (110) | 87 (102) | |
| p-p70 S6K | # of tissue samples | 7 | 6 | 13 |
| Mean score (SD) | 261 (38) | 285 (16.4) | 272 (31) | |
| EGFR | # of tissue samples | 10 | 9 | 19 |
| Mean score (SD) | 0 (0) | 1 (3) | 1 (2) | |
a
Samples were from the following metastatic sites: liver (5), skin/soft tissue (5), lymph nodes (4), brain (3), bone (2), lung (1), mediastinum (1), pleural fluid (1)
b
Scores represent the products of the percent positivity score (0–100) and intensity score (0–3) for each antibody
c
Dp-32/t-Dp DARPP-32 plus t-DARPP
d
P 0.09, Wilcoxon rank-sum test. All other P-values were greater than 0.09